Nesher Technologies, Inc.
Nanobiotech for smarter diagnostics and cutting-edge biomedical research

About Us

Nesher Technologies, Inc. (NTI) is a private nanobiotech company located in Los Angeles, CA. NTI was established to commercialize an innovative ultrasensitive biodetection technology pioneered at the University of California Los Angeles (UCLA) Single Molecule Biophysics Laboratory. The lab is headed by internationally renowned Professor Shimon Weiss who founded NTI. He has a long-standing record of accomplishments in the field of single molecule detection and nanobiotechnology, including development of fluorescent semiconductor nanocrystals (Quantum Dots) as biological probes which led to the foundation of Quantum Dot Corp (QDC; recently acquired by Invitrogen/Life Technologies).

The Company has exclusively licensed the patent-protected ALEX technology from UCLA and focused its initial research and development activities on instrumentation and reagent development for medical diagnostics in the areas of oncology, infectious diseases, neurogenetic disorders, and bioterror threats, as well as on instrumentation for life sciences applications. These activities, funded through several National Institutes of Health (NIH) grants totaling $3.2M, allowed proof-of-principle demonstration for use of the ALEX technology in clinical diagnostics applications (recently published in Clinical Chemistry) as well as filing of three provisional patent applications by NTI.

For further information about Nesher Technologies, Inc. and potential investment opportunities, please This email address is being protected from spambots. You need JavaScript enabled to view it.